Project Details
Projekt Print View

Evaluation of allogeneic cell transplantation in acute myeloid leukemia I (ETAL I)

Subject Area Hematology, Oncology
Term from 2010 to 2014
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 130027305
 

Final Report Abstract

In summary, the results of this prospective randomized trial, the first of its kind, suggest that allogeneic HCT performed immediately after achievement of a first CR in patients with cytogenetically defined intermediate-risk AML ≤ 60 years of age and an available sibling or unrelated donor does not seem to convey a survival advantage. Despite an increased incidence of relapse after conventional consolidation chemotherapy, salvage allogeneic HCT can be regarded as an effective treatment option. The early identification and allocation of a suitable donor during induction therapy seems to be warranted in intermediate-risk patients being eligible transplant candidates. However, allogeneic HCT in CR1 significantly reduced the relapse risk and is was not associated with relevant impairments in quality of life. With the advent of personalized strategies for monitoring of residual disease, delayed allogeneic transplantation can be regarded as a valid treatment algorithm in intermediate-risk AML with an available donor.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung